Chad C. Bjorklund

2.5k total citations · 1 hit paper
49 papers, 1.7k citations indexed

About

Chad C. Bjorklund is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Chad C. Bjorklund has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 40 papers in Hematology and 17 papers in Oncology. Recurrent topics in Chad C. Bjorklund's work include Multiple Myeloma Research and Treatments (39 papers), Protein Degradation and Inhibitors (30 papers) and Ubiquitin and proteasome pathways (16 papers). Chad C. Bjorklund is often cited by papers focused on Multiple Myeloma Research and Treatments (39 papers), Protein Degradation and Inhibitors (30 papers) and Ubiquitin and proteasome pathways (16 papers). Chad C. Bjorklund collaborates with scholars based in United States, United Kingdom and Canada. Chad C. Bjorklund's co-authors include Robert Z. Orlowski, Deborah J. Kuhn, Laura A. Bruins, Rafaël Fonseca, Jessica Schmidt, A. Keith Stewart, P. Leif Bergsagel, Yuan Xiao Zhu, Esteban Braggio and Xiu-Bao Chang and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Blood.

In The Last Decade

Chad C. Bjorklund

48 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

2011 461 citations Chad C. Bjorklund, Robert Z. Orlowski et al. Blood profile →

Peers

Countries citing papers authored by Chad C. Bjorklund

Since Specialization

Citations

This map shows the geographic impact of Chad C. Bjorklund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chad C. Bjorklund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chad C. Bjorklund more than expected).

Fields of papers citing papers by Chad C. Bjorklund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chad C. Bjorklund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chad C. Bjorklund. The network helps show where Chad C. Bjorklund may publish in the future.

Co-authorship network of co-authors of Chad C. Bjorklund

This figure shows the co-authorship network connecting the top 25 collaborators of Chad C. Bjorklund. A scholar is included among the top collaborators of Chad C. Bjorklund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chad C. Bjorklund. Chad C. Bjorklund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide 2024 ·Blood ·Tracy T. Chow, Nicholas Stong, (unknown), Chad C. Bjorklund, Antonina V. Kurtova, Keyur Desai, (unknown), (unknown), Phillip J. Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo	1
2	Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma 2024 ·Blood ·Sarah Gooding, (unknown), Warren L. Baker, (unknown), Simon Davis, Roman Fischer, (unknown), Joanna Hester, Fadi Issa, Srinivasa R. Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P. Cribbs, Alessandro Laganà, Udo Oppermann	2
3	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma 2021 ·Blood ·Chad C. Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, (unknown), Jessica Katz, Paulo Maciag, Patrick R. Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta	6
4	Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations 2020 ·Blood ·Michael Amatangelo, Chad C. Bjorklund, Peilin Ma, (unknown), William E. Pierceall, Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat, Sundar Jagannath, Jeffrey A. Zonder, Monique C. Minnema, Albert Oriol, Jeremy T. Larsen, Ashraf Badros, Paula Rodríguez‐Otero, Pieter Sonneveld, Tuong Vi Nguyen, Kevin Hong, April Sorrell, Anjan Thakurta	7
5	Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN 2019 ·Leukemia ·Chad C. Bjorklund, Jian Kang, Michael Amatangelo, Ann Polonskaia, Mark H. Katz, Hsiling Chiu, Suzana S. Couto, Maria Wang, Yan Ren, María Ortiz, Fadi Towfic, (unknown), William E. Pierceall, Anjan Thakurta	144
6	Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) 2017 ·Blood ·Xiaozhong Qian, Meletios Α. Dimopoulos, Michael Amatangelo, Chad C. Bjorklund, Katja Weisel, Enrique M. Ocio, Xin Yu, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau, Anjan Thakurta	1
7	Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma 2016 ·British Journal of Haematology ·Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama Krishna Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel, Antonia Lopez‐Girona	40
8	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia 2015 ·Clinical Cancer Research ·Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing‐Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski	16
9	Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 2015 ·Blood Cancer Journal ·Chad C. Bjorklund, Ling Lu, Jian Kang, Patrick R. Hagner, Courtney G. Havens, Michael Amatangelo, (unknown), Yan Ren, Suzana S. Couto, Michael A. Breider, Yuhong Ning, Anita K. Gandhi, Tom Daniel, Rajesh Chopra, Anke Klippel, Anjan Thakurta	154
10	A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples 2015 ·Applied immunohistochemistry & molecular morphology ·Yan Ren, Maria Wang, Suzana S. Couto, Donna E. Hansel, Karen Miller, Antonia Lopez‐Girona, Chad C. Bjorklund, Anita K. Gandhi, Anjan Thakurta, Rajesh Chopra, Michael A. Breider	13
11	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone 2014 ·Leukemia ·Enrique M. Ocio, Diego Fernández‐Lázaro, Laura San‐Segundo, Lucía López‐Corral, Luís A. Corchete, Norma C. Gutiérrez, Mercedes Garayoa, Teresa Paíno, Antonio García-Gómez, María del Mar Delgado, Juan Carlos Montero, Elena Díaz‐Rodríguez, María‐Victoria Mateos, Atanasio Pandiella, Suzana S. Couto, (unknown), Chad C. Bjorklund, Jesús F. San Miguel	58
12	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737 2014 ·PLoS ONE ·Dongmin Gu, Shuhong Wang, Isere Kuiatse, Hua Wang, Jin He, Yun Dai, Richard J. Jones, Chad C. Bjorklund, Jing Yang, Steven Grant, Robert Z. Orlowski	26
13	The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1 2013 ·Journal of Pharmacology and Experimental Therapeutics ·Richard J. Jones, Dongmin Gu, Chad C. Bjorklund, Isere Kuiatse, Alan T. Remaley, Tarig Bashir, Veronique Vreys, Robert Z. Orlowski	24
14	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications 2013 ·Leukemia ·Chad C. Bjorklund, Veerabhadran Baladandayuthapani, Hui‐Yi Lin, Richard J. Jones, Isere Kuiatse, Hua Wang, Jinling Yang, Jatin J. Shah, Sheeba K. Thomas, M Wang, D. Weber, Robert Z. Orlowski	99
15	Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance 2013 ·Blood ·Anjan Thakurta, Anita K. Gandhi, Michelle F. Waldman, Chad C. Bjorklund, Suzanne Lentzsch, Stephen Schey, Yolanda Calle, (unknown), Robert Z. Orlowski, Anup Madan, Yuhong Ning, Derek Mendy, Antonia Lopez‐Girona, Peter Schäfer, Hervé Avet‐Loiseau, Rajesh Chopra	3
16	Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA 2012 ·Molecular Cancer Therapeutics ·Richard J. Jones, Chad C. Bjorklund, Veerabhadran Baladandayuthapani, Deborah J. Kuhn, Robert Z. Orlowski	46
17	Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma 2012 ·Blood ·Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Richard Woessner, Chad C. Bjorklund, Wencai Ma, R. Eric Davis, (unknown), Hua Wang, Timothy Madden, Caimiao Wei, Veerabhadran Baladandayuthapani, Michael Wang, Sheeba K. Thomas, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski	143
18	Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide 2010 ·Journal of Biological Chemistry ·Chad C. Bjorklund, Wencai Ma, Zhiqiang Wang, R. Eric Davis, Deborah J. Kuhn, Steven M. Kornblau, Michael Wang, Jatin J. Shah, Robert Z. Orlowski	97
19	Attenuation of DNA charge transport by compaction into a nucleosome core particle 2006 ·Nucleic Acids Research ·Chad C. Bjorklund	22
20	Reduction of 13-Deoxydoxorubicin and Daunorubicinol Anthraquinones by Human Carbonyl Reductase 2005 ·Cardiovascular Toxicology ·Andrew M. Slupe, Berea A. R. Williams, (unknown), Laura M. Lee, Toby Primbs, (unknown), Chad C. Bjorklund, Don L. Warner, Jeffrey M. Peloquin, Susan E. Shadle, Hervé A. Gambliel, Barry J. Cusack, Richard D. Olson, Henry A. Charlier	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact